In this study, we leverage our rapid antibody discovery platform to engineer a novel human anti-TIM-4 antibody that potently inhibits efferocytosis, thus improving tumor cell antigen presentation and immune cell infiltration. The gene discussed is TIMD4; the disease is neoplasm.